Temporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translation
{{output}}
Introduction: The clinical translation of pluripotent stem cell-derived therapies has entered a new phase following conditional approval of first-in-class allogeneic induced pluripotent stem cell (iPSC)-derived products in Japan.... ...
